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Undone science and blind spots in medical treatment research 
Abstract 
Age-related Macular Degeneration (AMD) is a serious eye disease. Two similar drugs, Lucentis and 
Avastin, are available to slow the progression of wet AMD. Research has been carried out on the highly 
profitable drug Lucentis, so governments have licensed it for use, whereas equivalent research and formal 
licensing of Avastin for treatment of eye disease has been delayed and discouraged. This is a case 
illustrating the problem of undone science: research in socially beneficial areas may be neglected for 
commercial or political reasons. 
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Undone science and blind spots  
in medical treatment research 
 
Tom Cleary
Mr. Silverless and the story of two eye drugs 
Mr. Cosmo Silverless was an active 80-
year-old Australian at the time his central vision 
began to fail in July 2005. He not only enjoyed 
travelling but was also researching local coal mining 
history with a few colleagues. He reports:  
 
This has involved field visits, interviewing 
older people, research at Wollongong 
Library and the University, reading many 
books and writing. It is imperative that I 
retain at least partial eyesight to continue 
with this work.  
 
 He suffers from chronic kidney disease and is on 
dialysis and exchange bags four times daily:  
 
This condition has put a stop to major 
activities such as flying and travelling long 
distances by bus or train. Holidays are 
therefore curtailed. 
 
 Finally, he has severe arthritis in both knees which 
makes walking difficult:  
 
Life would be made far more difficult if I 
could no longer drive. 
  
Unfortunately Mr Silverless is one of the 
thousands of elderly Australians who live with the 
effects of an eye disease called Age-related Macular 
Degeneration (AMD). The macular of the eye is 
responsible for central vision. This small area of the 
retina enables the eye to see detail required for 
reading and driving. Mr Silverless is already legally 
blind in his right eye due to damage to its macula. 
He needs monthly injections into his left eyeball to 
keep his left macular area healthy and keep him 
from losing his remaining central vision.  
 
AMD can leave people over fifty years old with 
little or no central vision. It is a major cause of 
impaired vision in Australia (AIHW 2005). It can 
result in a person being legally blind and unable to 
easily perform everyday tasks that require the use of 
detailed vision such as reading, writing and even 
facial recognition. The central vision loss occurs 
slowly with the dry form of AMD or can be lost 
suddenly with the wet form of AMD (Guymer 
2007). The wet form of AMD has serious 
consequences for a large number of people but since 
2005 can now be treated with a number of drugs 
which target the new blood vessel growth at the 
macular.  
Avastin (with the generic name 
bevacizumab) and Lucentis (generic name 
ranibizumab) are potent forms of a drug that blocks 
blood vessel growth factors. They were the product 
of an attempt to cure cancer by restricting the blood 
supply to growing tumours (Hess 2006). Both of 
these drugs were developed by the pharmaceutical 
company Genentech.  
Avastin eventually received FDA approval 
for treatment of some forms of cancer and is quite 
expensive at many thousands of dollars per 
treatment (Hurwitz and Kabbinavar 2005). But 
Avastin was found to also be effective at controlling 
wet AMD when given in very small doses allotted 
from the larger cancer treatment dose which made it 
very cheap (Rosenfeld, et al. 2005).  
Lucentis was designed to be exclusively used in 
the treatment of wet AMD and underwent extensive 
clinical trials in order to demonstrate its safely and 
efficacy and was delivered to the market in single 
dose form for the treatment of wet AMD 
(Steinbrook 2006). Unlike Avastin which was very 
cheap, Lucentis was very expensive per treatment 
dose. This unprecedented scenario led to increased 
costs in some countries such as Australia which 
supported and subsidised the use of Lucentis 
(O'Shea 2010). In many countries the Avastin-
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versus-Lucentis debate has brought about a 
systematic challenge to the status quo of the way 
pharmaceuticals are researched and delivered, such 
as in the US where research challenging the position 
of Lucentis as the standard treatment of wet AMD is 
continuing (CATT Research group 2011). 
In Australia the case of Mr Silverless highlights 
the challenges of meeting best practice clinical 
standards and conforming to a complex medical 
system. Mr Silverless first lost the central vision of 
the right eye in July 2005. When Avastin became 
available in Australia in April 2006 Mr Silverless 
was given an injection into his right eye and it 
reduced the swelling of the retina but the damage 
was already too great to have any improvement in 
vision and so no further drug treatment was given to 
the right eye. As soon as the left eye showed signs 
of vision blur and wet AMD blood vessel growth in 
June 2007 the eye was treated with an injection of 
Avastin and the central vision returned to normal. At 
the time the similar drug Lucentis was not used 
because it was not yet subsidised by the Australian 
government and at $2000 per injection was too 
expensive (Avastin was only $100 per injection). Mr 
Silverless received a number of monthly injections 
of Avastin but then his treatment drug was changed 
to Lucentis when it became fully subsidised by the 
Australian Government. This treatment of wet AMD 
with injections into the eye of both Avastin and 
Lucentis is invasive and risky as the treatment is 
designed to improve the central vision but, for 
example, there is a risk that the vision in the whole 
eye can be lost due to potential side effects of the 
injection (Wijngaarden and Qureshi 2008). 
Despite the risks and the ongoing expense the 
ability to maintain Mr Silverless’ central vision is 
vital to ensuring his quality of life. Lucentis 
treatment is heavily subsidised by the Australian 
Government for the treatment of wet AMD. Over 
$18,000 per year is required to treat Mr Silverless’ 
left eye with monthly Lucentis injections. In 2009 
over $150 million was spent on Lucentis through the 
Australian Government’s Pharmaceutical Benefits 
Scheme. This excessive cost has been noted in the 
literature:  
 
An ophthalmologist undertaking 30 
injections on their morning list would spend 
just $535.77 of public money on 
pharmaceuticals with Avastin. By contrast, 
if they used Lucentis they would spend $59, 
460 (O’Shea 2011: 12).  
So although Avastin costs less than one tenth of 
the price of Lucentis, the Australian Government’s 
own policies and the apparent lack of scientific 
testing of Avastin means that it will be some time 
before cheaper drug treatments are widely available 
through the Australian health system despite the 
objections of the treating clinicians (Taylor, et al. 
2007).  
There is little incentive for the pharmaceutical 
and biotechnology companies to conduct this costly 
research on the cheaper drug (Mitchell, et al. 2011). 
Health systems across the developed world have 
faced various barriers to conducting their own 
clinical trials on the cheaper drug such as 
Genentech’s attempts to restrict the use of Avastin 
(Goldstein and Chase 2007). This dilemma, in 
which the lack of research on Avastin has held back 
the reform of drug treatments for wet AMD, is an 
example of what is known as the problem of 
undone science. Medical retinal diagnosis and 
treatment has become more effective since 2005 but 
AMD is such a huge problem for people in the 
community that much more needs to be done to be 
able to mitigate the impact of this blinding disease.  
It has long been recognised that some research 
priorities gain precedence over others for political 
and economic rather than clinically derived reasons 
(Richards 1991). More specifically David Hess 
describes science that is left incomplete or under-
resourced for political and economic reasons as “the 
problem of undone science”. According to Hess this 
undone science can be the result of a systemic effort 
by elites who put structures in place that keep 
research from being completed (Hess 2007). 
The concept of undone science has emerged 
from the sociology of science as a useful tool for 
highlighting the politics of research priorities where 
alternatives that are less profitable can be readily 
marginalized (Frickel, et al. 2009). The undone 
science of wet Age-related Macular Degeneration 
treatment research can be used to illustrate broader 
themes related to the production and direction of 
biomedical sciences.  
The key to understanding the power of the 
undone science of wet AMD treatment is to see the 
research that is deliberately left under resourced as a 
way of maximising short term profit of 
pharmaceutical companies from the patent system. 
The drugs Lucentis and Avastin can slow and often 
reverse this loss of vision (Mitchell 2011). These 
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two drugs are very similar and mainly differ in the 
way that the much cheaper drug Avastin has 
struggled to attract funding for large scale clinical 
trials research (Harvey, et al. 2011). In fact these 
drugs were derived from the same humanised mouse 
antibody and this was seen as an early threat to 
potential profits of Lucentis (Goldstein and Chase 
2007). The Avastin research that has been left to one 
side is part of a broader group of visual problems 
that have been given a lower priority by market 
forces guiding much of the research funding 
(Wright, et al. 2007). 
This paper seeks to investigate how the undone 
science of medical retinal drug treatments came to 
influence the options available to treat someone like 
Mr Silverless, and, more broadly, how the problem 
of undone science came to increase the financial and 
treatment burden of Age-related Macular 
Degeneration on the Australian community.  
 
The role of social theory in the reshaping of 
health care 
Health professionals take pride in the ongoing 
search for best practice. Often evidence based 
studies are performed that demand the practitioner 
rethink their approach to an area of expertise 
(DeMets 2005). Much of the time these studies 
come from an area of scientifically recognised 
research, but social theory can also influence the 
way a health practitioner can think and the way a 
health system can function. Each clinical encounter 
is an opportunity to apply and adapt best practice 
both within the clinic and in the society at large. A 
clinical encounter is mediated by communication 
occurring in an essentially social space which is one 
of the ways the tools provided by social theory can 
find immediate application (Leder 1990). Social 
reconstruction is a process offered by recent 
theorists that in some ways invites a rethinking of 
the way technoscientific practices are justified. It is 
a process that involves critical analysis of recent 
historical cases and has been used in such diverse 
areas as the greening of industries, non-weapon 
based defence and alternative medicine 
(Woodhouse, et al. 2002). Reconstruction of a social 
practice, especially a technoscientific social practice 
prone to technocratic absolutism such as evidence 
based medicine, is an idea that can be important to 
achieving significant reform. Recent political and 
economic crises underline that the lack of reform 
and the unsustainable expense of current health 
systems represents a fundamental challenge to civil 
society. 
At certain stages during the period 2005–2010, 
the main problem with Avastin use was the lack of 
comprehensive clinical trials research, hence 
creating a problem of undone science for those who 
may have wished to justify its use as a treatment for 
wet AMD. As Guymer points out in the March 2007 
Medical Journal of Australia (just three months 
before Mr Silverless’ left eye was affected by 
AMD):  
 
No prospective randomised studies 
comparing ranibizumab (Lucentis) and 
bevacizumab (Avastin) have taken place, 
although there are plans for such a trial 
through the US National Eye Institute. Until 
the results of such a comparative trial are 
forthcoming, government and the community 
face a dilemma of whether to approve and 
subsidise the well studied but expensive drug 
ranibizumab or delay that decision and 
therefore condone the off-label use of a drug 
(Avastin) that has not been submitted to the 
rigours of a randomised clinical trial nor 
studies to the extent that we expect before a 
new drug is introduced (Guymer 2007: 276).  
 
Despite the recognition that wet AMD is an 
extraordinary economic burden to the community 
and that it has an enormous impact on quality of life, 
many studies simply use economic and 
epidemiological data to argue for the relative 
benefits of funding research, and subsidising 
treatment and diagnosis of wet AMD. This may be 
due to ongoing controversy surrounding the 
commercialisation of this area of medicine. Studies 
that focus on using preventive techniques to reduce 
the social impact of AMD and research in low 
vision and rehabilitation of visual function in those 
people affected by AMD have an important role to 
play in addressing this disabling condition (Smith, et 
al. 2001). 
This case study of Anti-VEGF treatment research 
gave an opportunity to apply David Hess’ 
interpretation of undone science. In Hess’ (2006) 
chapter “Antiangiogenesis Research and the 
Dynamics of Scientific Fields” he identifies certain 
factors as important to the study of undone science: 
denaturalization of the material world, 
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universalization of values, expansion of scale and 
differentiation of institutions. Hess’ work examines 
how certain societal aspects of conducting research 
can create a process of uneven development. 
Denaturalization of the material world means 
that science and technology can tend to become 
more distanced from living entities over time. The 
idea of denaturalization leads to an understanding of 
the importance of identifying patentable substances, 
as opposed to substances and preventive techniques 
that may be effective but are deemed too natural to 
be patented and therefore more difficult to be 
converted into a successful drug treatment. In the 
case of Lucentis, which was produced specifically 
for the treatment of retinal blood vessels, the 
question of patent was uncomplicated and the ease 
of predicting an economic return meant that research 
could be funded.  
On the other hand Avastin was already available 
as a treatment of bowel cancer when it began to be 
used to treat retinal blood vessel growth. This meant 
that any research that was conducted on Avastin as a 
wet AMD treatment would need to be performed 
without the expectation of the same economic 
returns as Lucentis. Also, because successful 
Avastin research would hurt the profitability of 
Lucentis, it is not surprising that the company 
conducting Lucentis research would not support the 
funding of Avastin research. By denaturalizing the 
material world and creating patentable substances 
we can see in this case how the priority can quickly 
become conducting research in the most 
economically productive areas of a scientific field 
and allowing the silence of undone science to 
marginalize the less profitable alternatives 
(Nickisch, et al. 2009). 
Hess also describes the universalization of 
values, a tendency for fields of science to develop 
formal methodologies of dispute resolution such as 
the use of Randomised Controlled Trials (RCTs) in 
the area of clinical medicine. RCTs are recognized 
as the gold standard for evaluating treatment but 
also impose large costs and scale requirements on 
the required research. This makes the imperative to 
use the most economically viable substance more 
important when looking to make a profit on 
investment in drug treatment options. Phase I, II and 
III drug trials can cost many millions of dollars and 
are seen as important to ensure that new drug 
treatments are safe and effective.  
These experiments are conducted in a way that 
attempts to minimise certain forms of bias. But the 
social factors at play in undone science are rarely 
taken into account when addressing the case for and 
against using particular drug treatments. Because 
comprehensive research has not been conducted on 
Avastin as a treatment for wet AMD, the clinician 
who wishes to justify using this drug may point out 
that the potential bias of the observer is not the only 
relevant bias when evaluating the literature. The 
societal factors at play also need to be addressed in 
the way they shape the research available to the 
clinician. 
Expansion of scale is also identified by Hess as 
shaping the contours of research, where the cost and 
scale of laboratory sciences have expanded faster 
than the ability of public institutions to fund 
research. As the cost and scale out pace the public 
purse, many more organizations seek to bring new 
science to the public, some of which are only 
involved in order to realize a financial return on 
their investment. Thus the way these organizations 
go about their business can further shape the 
contours of scientific progress. This can be 
demonstrated in the case of the privately funded 
Lucentis and the public funding of Avastin wet 
AMD treatment research. The expansion of scale of 
science means that it is not always possible to 
conduct research in areas that are for the common 
good without a deliberate effort to coordinate public 
knowledge resources and work to limit the 
exploitative profiteering of engineered ignorance. 
So in scientific fields there can be lots of 
organizations, both public and private, and large 
amounts of money at stake. Hess shows the 
importance of the differentiation of these institutions 
in shaping science. Hess points out that conflicts 
regarding roles and organizational goals 
increasingly arise within and between various fields 
of action of science. In the case study of Lucentis 
and Avastin this differentiation of institutions has 
been identified as a challenge and an opportunity for 
bringing about organizational and political change 
that can help institutions evolve to serve the 
changing needs of the community. For example, 
public institutions such as hospitals and professional 
organisations can bring about reform of a scientific 
field by cooperating in ways that address the lack of 
research in an area where there is little hope of a 
financial return but huge cost savings for the 
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community (O'Shea 2011). Avastin may not be as 
profitable a treatment of wet AMD as Lucentis but 
there are potential benefits for institutions to 
cooperate in order to fund and conduct the relevant 
research and work together to incorporate the 




Overall an awareness of societal and historical 
aspects of technoscientific practices has been shown 
in recent literature to be important in the progress of 
science and the modernization of society (Kleinman 
2005). The incorporation into social studies of 
science of cases that demonstrate the extraordinary 
effect on the direction of scientific fields exerted by 
simply controlling the resources available to 
conduct research has been important to 
understanding science as a social practice (Proctor 
2008). Hess’ study of undone science, when applied 
to the treatment of wet AMD, is a robust example of 
how societal factors can be the key consideration for 
people, both patients and practitioners, in their 
everyday encounter with clinical best practice.  
An understanding of the implications of 
denaturalization of the material in the current era of 
patent for profit is important for those seeking 
reform. When trying to find ways to resolve 
disputes, also essential is finding ways to break 
down the problems of institutional differentiation, 
expansion of scale and universalization of values. 
Civil society should learn to be less tolerant of 
convenient blind spots in scientific knowledge that 
exist only to advantage those willing to compromise 
society’s best interest for short term profit. Thus an 
ongoing examination of the way that progress in 
biosciences can be interpreted in terms of social 
theory such as that of undone science is important 
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